Statistical Analysis
Data were analyzed from June 30, 2016, to November 1, 2022. This trial was designed to evaluate the noninferiority of the EP vs EC-P regimens. The test was designed with 80% power at the 1-sided α of .05. The trial assumed a 5-year DFS of 83% for the EC-P regimen.The statistical analysis was performed using SPSS software, version 23.0 (IBM Corporation), and the GraphPad Prism program, version 7.0 (GraphPad Software). All efficacy analyses were performed in the intention-to-treat (ITT) population. We used the χ